196 related articles for article (PubMed ID: 31895095)
1. Metastatic Cutaneous Basal Cell Carcinoma: Report of 2 Cases Preceding the Hedgehog Pathway Antagonists Era.
Bisceglia M; Panniello G; Nirchio V; Sanguedolce F; Centola M; Ben-Dor DJ
Adv Anat Pathol; 2020 Mar; 27(2):98-111. PubMed ID: 31895095
[TBL] [Abstract][Full Text] [Related]
2. Metastatic Basal Cell Carcinoma of the Skin: A Comprehensive Literature Review, Including Advances in Molecular Therapeutics.
Bisceglia M; Panniello G; Galliani CA; Centola M; D'Errico MM; Minenna E; Tucci FA; Ben-Dor DJ
Adv Anat Pathol; 2020 Sep; 27(5):331-353. PubMed ID: 32618586
[TBL] [Abstract][Full Text] [Related]
3. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449).
Meani RE; Lim SW; Chang AL; Kelly JW
Australas J Dermatol; 2014 Aug; 55(3):218-21. PubMed ID: 25117162
[TBL] [Abstract][Full Text] [Related]
4. Metastatic basal cell carcinoma of the posterior neck: case report and review of the literature.
Gropper AB; Girouard SD; Hojman LP; Huang SJ; Qian X; Murphy GF; Vleugels RA
J Cutan Pathol; 2012 May; 39(5):526-34. PubMed ID: 22515224
[TBL] [Abstract][Full Text] [Related]
5. Malignant melanoma metastatic to a basal cell carcinoma simulating the pattern of a basomelanocytic tumor.
Busam KJ; Halpern A; Marghoob AA
Am J Surg Pathol; 2006 Jan; 30(1):133-6. PubMed ID: 16330954
[TBL] [Abstract][Full Text] [Related]
6. [Basal cell carcinoma of prostate: a report of three cases].
Liu Z; Ma LL; Zhang SD; Lu M; Tian Y; He Q; Jin J
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 48(4):720-724. PubMed ID: 29263520
[TBL] [Abstract][Full Text] [Related]
7. Hedgehog pathway inhibitor in combination with radiation therapy for basal cell carcinomas of the head and neck : First clinical experience with vismodegib for locally advanced disease.
Schulze B; Meissner M; Ghanaati S; Burck I; Rödel C; Balermpas P
Strahlenther Onkol; 2016 Jan; 192(1):25-31. PubMed ID: 26449347
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
9. A Practical Guide for the Follow-Up of Patients with Advanced Basal Cell Carcinoma During Treatment with Hedgehog Pathway Inhibitors.
Dessinioti C; Plaka M; Soura E; Mortaki D; Papaxoinis G; Gogas H; Stratigos AJ
Oncologist; 2019 Aug; 24(8):e755-e764. PubMed ID: 31073024
[TBL] [Abstract][Full Text] [Related]
10. Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome.
Ozgur OK; Yin V; Chou E; Ball S; Kies M; William WN; Migden M; Thuro BA; Esmaeli B
Am J Ophthalmol; 2015 Aug; 160(2):220-227.e2. PubMed ID: 25935097
[TBL] [Abstract][Full Text] [Related]
11. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
12. Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma.
Mathis J; Doerr T; Lin E; Ibrahim SF
Dermatol Surg; 2019 Jan; 45(1):17-25. PubMed ID: 30586344
[TBL] [Abstract][Full Text] [Related]
13. Destruction of the orbit and globe by recurrence of basal cell carcinoma.
Chew R
Optometry; 2007 Jul; 78(7):344-51. PubMed ID: 17601572
[TBL] [Abstract][Full Text] [Related]
14. Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib.
Hehlgans S; Booms P; Güllülü Ö; Sader R; Rödel C; Balermpas P; Rödel F; Ghanaati S
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142876
[TBL] [Abstract][Full Text] [Related]
15. Rare basal cell metastasis of a basal-squamous skin collision tumour to the lung and axillary lymph node.
Li R; Lee G; Huang M; El-Sherief A
BMJ Case Rep; 2019 Oct; 12(10):. PubMed ID: 31585957
[TBL] [Abstract][Full Text] [Related]
16. Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.
Lacouture ME; Dréno B; Ascierto PA; Dummer R; Basset-Seguin N; Fife K; Ernst S; Licitra L; Neves RI; Peris K; Puig S; Sokolof J; Sekulic A; Hauschild A; Kunstfeld R
Oncologist; 2016 Oct; 21(10):1218-1229. PubMed ID: 27511905
[TBL] [Abstract][Full Text] [Related]
17. Advances in the treatment of Basal cell carcinoma: Hedgehog inhibitors.
Kudchadkar R; Lewis K; Gonzalez R
Semin Oncol; 2012 Apr; 39(2):139-44. PubMed ID: 22484185
[TBL] [Abstract][Full Text] [Related]
18. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
Sekulic A; Migden MR; Lewis K; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Dirix L; Hou J; Yue H; Hauschild A;
J Am Acad Dermatol; 2015 Jun; 72(6):1021-6.e8. PubMed ID: 25981002
[TBL] [Abstract][Full Text] [Related]
19. Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.
Leavitt E; Lask G; Martin S
Curr Treat Options Oncol; 2019 Nov; 20(11):84. PubMed ID: 31773379
[TBL] [Abstract][Full Text] [Related]
20. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
Dummer R; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Gogov S; Pallaud C; Yi T; Mone M; Chang AL; Cornélis F; Kudchadkar R; Trefzer U; Lear JT; Sellami D; Migden MR
J Am Acad Dermatol; 2016 Jul; 75(1):113-125.e5. PubMed ID: 27067394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
